Show simple item record

dc.contributor.authorA. Rahimi
dc.contributor.authorM. Faizi
dc.contributor.authorF. Talebi
dc.contributor.authorF. Noorbakhsh
dc.contributor.authorF. Kahrizi
dc.contributor.authorN. Naderi
dc.date.accessioned2017-09-18T10:49:12Z
dc.date.available2017-09-18T10:49:12Z
dc.date.issued2015-04-02
dc.identifier.issn18737544
dc.identifier.urihttp://dsp.sbmu.ac.ir/xmlui/handle/123456789/67145
dc.description.abstract© 2015 IBRO. Cannabinoids (CBs) have recently been approved to exert broad anti-inflammatory activities in experimental models of multiple sclerosis (MS). It has been demonstrated that these compounds could also have effects on neurodegeneration, demyelination, and autoimmune processes occurring in the pathology of MS. However, the clinical use of CBs is limited by their psychoactive effects. Among cannabinoid compounds, cannabidiol (CBD) and palmitoylethanolamide (PEA) have no psychotropic activities. We induced experimental autoimmune encephalomyelitis (EAE), a model of MS, by injecting myelin oligodendrocyte glycoprotein (MOG) to C57BL/6 mice. We assessed the effects of CBD, PEA, and co-administration of CBD and PEA on neurobehavioral scores, immune cell infiltration, demyelination, axonal injury, and the expression of inflammatory cytokines by using histochemistry methods and real-time RT-PCR. Treatment with either CBD (5. mg/kg) or PEA (5. mg/kg) during disease onset reduced the severity of the neurobehavioral scores of EAE. This effect of CBD and PEA was accompanied by diminished inflammation, demyelination, axonal damage and inflammatory cytokine expression while concurrent administration of CBD (5. mg/kg) and PEA (5. mg/kg) was not as effective as treatment with either drug per se. These results suggest that, CBD and PEA, non-psychoactive CBs, attenuate neurobehavioral deficits, histological damage, and inflammatory cytokine expression in MOG-immunized animals. However, there is an antagonistic interaction between CBD and PEA in protection against MOG-induced disease.
dc.sourceNeuroscience
dc.subjectCannabidiol
dc.subjectCannabinoid
dc.subjectEAE
dc.subjectMultiple sclerosis
dc.subjectPalmitoylethanolamide
dc.titleInteraction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice
dc.journal.volume290
dc.identifier.doi10.1016/j.neuroscience.2015.01.030
dc.journal.pages279-287
dc.contributor.authorid56513333500
dc.contributor.authorid6508118042
dc.contributor.authorid56513817000
dc.contributor.authorid6603347687
dc.contributor.authorid56514158600
dc.contributor.authorid23088871800
dc.contributor.citation56513333500|60018934|A. Rahimi
dc.contributor.citation6508118042|60018934|M. Faizi
dc.contributor.citation56513817000|101813587|F. Talebi
dc.contributor.citation6603347687|60027708|F. Noorbakhsh
dc.contributor.citation56514158600|60018934|F. Kahrizi
dc.contributor.citation23088871800|60018934|N. Naderi
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934
dc.contributor.affiliationid101813587
dc.contributor.affiliationid60027708
dc.contributor.affiliationid60018934
dc.contributor.affiliationid60018934


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record